T
Tanja Schjødt Jørgensen
Researcher at Copenhagen University Hospital
Publications - 46
Citations - 523
Tanja Schjødt Jørgensen is an academic researcher from Copenhagen University Hospital. The author has contributed to research in topics: Psoriatic arthritis & Medicine. The author has an hindex of 10, co-authored 36 publications receiving 402 citations. Previous affiliations of Tanja Schjødt Jørgensen include University of Copenhagen & Frederiksberg Hospital.
Papers
More filters
Journal ArticleDOI
Association of Exercise Therapy and Reduction of Pain Sensitivity in Patients With Knee Osteoarthritis: A Randomized Controlled Trial
Marius Henriksen,L. Klokker,Thomas Graven-Nielsen,Cecilie Bartholdy,Tanja Schjødt Jørgensen,Elisabeth Bandak,Bente Danneskiold-Samsøe,Robin Christensen,Henning Bliddal +8 more
TL;DR: In this paper, the effects of exercise on pressure-pain sensitivity in patients with knee OA were investigated in a randomized controlled trial, where participants were assigned to 12 weeks of supervised exercise therapy (ET; 36 sessions) or a no attention control group (CG).
Journal ArticleDOI
Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study.
Lars Erik Kristensen,Tanja Schjødt Jørgensen,Robin Christensen,Henrik Gudbergsen,Lene Dreyer,Christine Ballegaard,Lennart T H Jacobsson,Vibeke Strand,Philip J. Mease,Jakob Kjellberg +9 more
TL;DR: The findings are suggestive of health inequity for patients with PsA and call for individual preventive measures and societal action.
Journal ArticleDOI
Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis
Simon Tarp,Daniel E. Furst,Daniel E. Furst,Daniel E. Furst,Maarten Boers,George Luta,Henning Bliddal,Ulrik Tarp,Karsten Asmussen,Birgitte Brock,Anna Dossing,Tanja Schjødt Jørgensen,Steffen Thirstrup,Robin Christensen +13 more
TL;DR: confidence in the estimates was low due to lack of head-to-head comparison trials and imprecision in indirect estimates, but the analysis found potential differences in rates of SAEs, which suggest caution should be taken when deciding among available drugs.
Journal ArticleDOI
Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry
Tanja Schjødt Jørgensen,Lars Erik Kristensen,Robin Christensen,Henning Bliddal,Tove Lorenzen,Michael Sejer Hansen,Mikkel Østergaard,Jørgen Juncher Jensen,Lida Zanjani,T. Laursen,Sheraz Butt,Mette Yde Dam,Hanne Merete Lindegaard,Jakob Espesen,Oliver Hendricks,Prabhat Kumar,Anita Kincses,L. Larsen,Marlene Andersen,Esben K Næser,D V Jensen,Jolanta Grydehøj,Barbara Unger,Ninna Dufour,Vibeke Sørensen,Sara Vildhøj,Inger Marie Jensen Hansen,Johnny Lillelund Raun,Niels Steen Krogh,Merete Lund Hetland +29 more
TL;DR: Nearly one in five biologic treatments for RA was prescribed in Denmark as monotherapy, of which 70% were on monotherapy from bio-initiation and 30% wereOn monotherapy after cessation of a concomitant csDMARD.
Journal ArticleDOI
Impact of Comorbidities on Tumor Necrosis Factor Inhibitor Therapy in Psoriatic Arthritis: A Population-Based Cohort Study.
Christine Ballegaard,Pil Højgaard,Lene Dreyer,René Cordtz,Tanja Schjødt Jørgensen,Marie Skougaard,Simon Tarp,Lars Erik Kristensen +7 more
TL;DR: The objective of this population‐based cohort study was to investigate the impact of comorbidities on disease activity, treatment response, and persistence with the first‐tried tumor necrosis factor inhibitor (TNFi) in patients with psoriatic arthritis (PsA).